Chemometec A/S
F:CHY

Watchlist Manager
Chemometec A/S Logo
Chemometec A/S
F:CHY
Watchlist
Price: 41.78 EUR -3.42%
Market Cap: €727.1m

Chemometec A/S
Investor Relations

Chemometec A/S makes laboratory instruments and consumables used to count, analyze, and prepare cells. Its core products are automated cell counters and related reagents that help scientists measure how many cells they have, how healthy they are, and whether they are ready for further testing or production. Its customers are mainly pharmaceutical and biotech companies, research labs, and manufacturers working with cell-based medicines and biological testing. Chemometec earns money by selling the instruments themselves and, just as importantly, by supplying the single-use reagents and consumables that the instruments need to run. That mix gives the business a recurring revenue model: a customer may buy the machine once, but then keeps purchasing the consumables over time. The company sits in a specialized part of the life-science tools market, where accuracy, ease of use, and consistency matter more than low price.

Show more
Loading...
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Martin Helbo Behrens
CEO & COO
No Bio Available
Mr. Hans Martin Glensbjerg
Deputy Chairman & Senior Advisor
No Bio Available
Mr. Kim Nicolajsen
Chief Financial Officer
No Bio Available
Mr. Christopher Runchel M.Sc., Ph.D.
Chief Sales Officer
No Bio Available
Marta Anglada Planaguma
Chief Marketing & Strategy Officer
No Bio Available
Ms. Lisbet Helles
Head of Marketing
No Bio Available
Mr. Søren Kjærulff
Head of R&D
No Bio Available
Mr. Bo Melholt Nielsen
Chief R&D Officer and Physicist & Project Manager
No Bio Available

Contacts

Address
ALLEROED
Gydevang 43
Contacts
+4548131020.0
chemometec.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett